Bernhard Suter
Epilepsy · Houston, TXNPI 1740415801
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,750 of the $5,841 with a category attached, or 81.3%. UCB SA accounts for 81.3% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $5,780, more than ten times the $27 reported in 2023.
Across 6 payments — averaging $973.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$5K
- UCB, Inc.$1K
- Acadia Pharmaceuticals Inc$35
- Immedica Pharma US, Inc.$27
Across 32 payments — averaging $21,519 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acadia Pharmaceuticals Inc$571K
- Immedica Pharma US, Inc.$100K
- UCB SA$18K
What the payments were for
- Consulting fees$4,75081%
- Travel & lodging$91316%
- Food & beverage$1793%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB SA | 1 | $4,750 |
| UCB, Inc. | 3 | $1,030 |
| Acadia Pharmaceuticals Inc | 1 | $35 |
| Immedica Pharma US, Inc. | 1 | $27 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Fintepla$5,780
How this compares
$5,841 in reported general payments places this provider in the 75th percentile of 36 epilepsy providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| DaybueTrofinetide | 21 | $1,010,962 |
| BanzelRufinamide | 12 | $27,315 |
| KeppraLevetiracetam | 13 | $23,290 |
| FycompaPerampanel | 14 | $17,899 |
| TrileptalOxcarbazepine | 14 | $13,082 |
| Levetiracetam | 27 | $1,732 |
| Lamotrigine | 22 | $511 |
| Zonisamide | 16 | $494 |
| Buspirone Hcl | 24 | $151 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncDaybue | $35 | $1,010,96221 claims |
| UCB SAKeppra | $4,750 | $23,29013 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 36 epilepsy providers in Texas.
Other epilepsy in Houston
- Irfan AliHouston$6K
- James RivielloHouston$3K
- Rohit KuruvillaHouston$2K
- Krystal SullyHouston$1K
- Stuti JoshiHouston$1K
- Adam DickeyHouston$824
- Yen TranHouston$818
- Ajlan AlshehriHouston$588
- Joshua CousinHouston$332
- Laura MastersHouston$272
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.